United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $567.74, for a total value of $5,393,530.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $23,000,850.62. This represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $578.43 on Wednesday. The company has a 50-day moving average of $564.81 and a 200-day moving average of $513.93. The company has a market capitalization of $24.55 billion, a price-to-earnings ratio of 21.35, a PEG ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $6.63 earnings per share. Sell-side analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current year.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the stock. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter worth about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.